Evidence map›Paper›PMID 41466480›Full record

ArticleJournal of microbiology and biotechnology2025

Gut Microbiota and Metabolomics Insights into the Gualou-Xiebai Herb Pair for Dyslipidemia and Atherosclerosis.

Ni Wang, Yanan Xu, Jiahui Li, Chunsheng Li, Zijian Liu, Zhenglong Li, Yarong Liu, Yexiang Zhang, An Zhou, Hongfei Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ni WangSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Yanan XuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Jiahui LiSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Chunsheng LiDepartment of Cardiovascular Surgery, Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P.R. China.
Zijian LiuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Zhenglong LiSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Yarong LiuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Yexiang ZhangThe First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, P.R. China.
An ZhouSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.
Hongfei WuSchool of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a chronic lipid driven arterial disease, dyslipidemia is one of the most critical risk factors for atherosclerosis (AS). The gut microbiota plays an important role in regulating host lipid metabolism disorders. Studies have shown that the herb "Gualou-Xiebai" (GLXB) can effectively regulate the blood lipid levels of ApoE

Indexed as

AtherosclerosisDrugs, Chinese HerbalDyslipidemiasGastrointestinal MicrobiomeAnimalsApolipoproteins ECaco-2 CellsCholesterolDiet, High-FatDisease Models, AnimalHumansLipid MetabolismMaleMetabolomicsMiceMice, Inbred C57BLApolipoproteins ECholesterolDrugs, Chinese HerbalcholesteroldyslipidemiaGualou-Xiebai herb pairgut microbiotashort-chain fatty acids

Identifiers

PMID41466480
PMCPMC12790985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.